ionis pharmaceuticals dawnzera - Search News

Order byBest matchMost fresh

News

DAWNZERA, FDA and hereditary angioedema

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Continue reading

PharmExec · 3h

FDA Approves Ionis Pharmaceuticals’ Dawnzera for Hereditary Angioedema

Fierce Pharma · 1d

Ionis steps into crowded HAE market with FDA approval for Dawnzera

Ionis Wins Approval For First RNA-Targeted Prophylactic for Rare Swelling Disease

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

TipRanks on MSN10h

Ionis Pharmaceuticals price target raised to $69 from $65 at Citi

Citi raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $69 from $65 and keeps a Buy rating on the shares following the FDA ...

6h

What's Going On With Takeda Stock On Friday?

Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results